At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 83 enrolled
Drug / intervention
GS-2829 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
In Brief
A Phase 1 clinical trial evaluating GS-2829, GS-6779, and 1 other intervention for Chronic Hepatitis B. Completed, enrolled 83 participants across 9 sites in 2 countries.
Detailed Summary
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesNew Zealand, Taiwan
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedMar 2023
Enrollment StartApr 2023
Primary CompletionJan 2025
TodayJul 2026
First PostedMar 16, 2023
Enrollment StartApr 3, 2023
Primary CompletionJan 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.3 years ago
Interventions
GS-2829biological
Administered intramuscularly
GS-6779biological
Administered intramuscularly
Placebobiological
Administered intramuscularly